Fin Trust Capital Advisors, LLC Intellia Therapeutics, Inc. Transaction History

Fin Trust Capital Advisors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 03, 2022	SELL	$58.27 - $118.99 $6,351 - $12,969	-109 Reduced 52.15%	100 $7,000
Q4 2021 Feb 14, 2022	SELL	$100.76 - $138.36 $80,608 - $110,688	-800 Reduced 79.29%	209 $25,000
Q3 2021 Nov 16, 2021	BUY	$132.37 - $176.78 $37,593 - $50,205	284 Added 39.17%	1,009 $135,000
Q2 2021 Aug 16, 2021	BUY	$60.88 - $161.91 $44,138 - $117,384	725 New	725 $117,000

344

98.4M

784K

713K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $734M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Fin Trust Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Fin Trust Capital Advisors, LLC with notifications on news.